“Irritable Bowel Syndrome (IBS) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Irritable Bowel Syndrome (IBS) market. A detailed picture of the Irritable Bowel Syndrome (IBS) pipeline landscape is provided, which includes the disease overview and Irritable Bowel Syndrome (IBS) treatment guidelines.
The assessment part of the report embraces in-depth Irritable Bowel Syndrome commercial assessment and clinical assessment of the Irritable Bowel Syndrome (IBS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable Bowel Syndrome (IBS) collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.
Irritable Bowel Syndrome (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, which causes cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. The symptoms can vary in severity and duration from person to person. However, they last at least three months for at least three days per month. IBS can cause intestinal damage in some cases. The condition is separate from inflammatory bowel disease and isn’t related to other bowel conditions.
Request for detailed sample pages: https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight
“The total diagnosed prevalence of IBS in 7MM was found to be 101.5 Million in 2017.”
Scope of the report
- The Irritable Bowel Syndrome pipeline report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products
- It comprises detailed profiles of Irritable Bowel Syndrome (IBS) therapeutic products with key coverage of developmental activities
- Detailed Irritable Bowel Syndrome (IBS) research and development progress and trial details
- Coverage of dormant and discontinued pipeline projects
Key pharma players involved:
1. Redhill Bio
2. Ardelyx Inc.
Table of Contents:
1. Report Introduction
2. Irritable Bowel Syndrome (IBS)
3. Irritable Bowel Syndrome (IBS) Current Treatment Patterns
4. Irritable Bowel Syndrome (IBS) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Irritable Bowel Syndrome (IBS) Late Stage Products (Phase-III)
7. Irritable Bowel Syndrome (IBS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Irritable Bowel Syndrome (IBS) Discontinued Products
13. Irritable Bowel Syndrome (IBS) Product Profiles
14. Irritable Bowel Syndrome (IBS) Key Companies
15. Irritable Bowel Syndrome (IBS) Key Products
16. Dormant and Discontinued Products
17. Irritable Bowel Syndrome (IBS) Unmet Needs
18. Irritable Bowel Syndrome (IBS) Future Perspectives
19. Irritable Bowel Syndrome (IBS) Analyst Review
20. Appendix
21. Report Methodology
Click here and get access to a free sample copy of the report.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/